ANNX

SEC source: 0001818520-26-000003 · form4-09252026_040908.xml · nonDerivative · entry 1

Love Douglas · CIK 0001818520 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 390,476

F1 · price: This transaction was executed in multiple trades in prices ranging from $3.815 to $3.829, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

F2 · balance_after: Includes 4,579 shares acquired on May 15, 2025 and 8,278 shares acquired on May 15, 2026, pursuant to the Issuer's Employee Stock Purchase Plan.

SEC source: 0001614869-26-000004 · form4-08122026_100821.xml · derivative · entry 1

Blumenkranz Mark S. · CIK 0001614869 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2036-08-10

F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from August 10, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service as a director on each such vesting date.

SEC source: 0001818525-26-000004 · form4-06152026_040601.xml · derivative · entry 2

Yednock Ted · CIK 0001818525 · EVP & CHIEF INNOVATION OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,646 shares

Expires 2026-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable.

SEC source: 0001818525-26-000004 · form4-06152026_040601.xml · nonDerivative · entry 1

Yednock Ted · CIK 0001818525 · EVP & CHIEF INNOVATION OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 184,807

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001315797-26-000002 · form4-06152026_040611.xml · derivative · entry 1

Satter Muneer A · CIK 0001315797 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.

SEC source: 0001373097-26-000001 · form4-06152026_040609.xml · derivative · entry 1

JONES WILLIAM A JR · CIK 0001373097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.

SEC source: 0001553338-26-000001 · form4-06152026_040615.xml · derivative · entry 1

Waddill William D. · CIK 0001553338 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.

SEC source: 0001900452-26-000001 · form4-06152026_040607.xml · derivative · entry 1

Cockroft Bettina M. · CIK 0001900452 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.

SEC source: 0001650126-26-000001 · form4-06152026_040605.xml · derivative · entry 1

Choi Jung · CIK 0001650126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.

SEC source: 0001824280-26-000005 · form4-06152026_040603.xml · derivative · entry 1

Carson William H. · CIK 0001824280 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.

SEC source: 0001315797-26-000001 · form4-05292026_090557.xml · nonDerivative · entry 1

Satter Muneer A · CIK 0001315797 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 10,342,134

F1 · shares: All shares were purchased by Alerce Medical Technology Partners, L.P. ("Alerce Medical"). The Reporting Person has sole voting and dispositive power over the shares held by Alerce Medical. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

F2 · ownership.nature: As of May 28, 2026, includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager, as applicable, and, in each such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 8,387,156 shares that are held by Alerce Medical for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest therein.

SEC source: 0001824280-26-000004 · form4-05132026_040507.xml · nonDerivative · entry 1

Carson William H. · CIK 0001824280 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,405

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted December 8, 2025.

SEC source: 0001824280-26-000003 · form4-04142026_080436.xml · nonDerivative · entry 1

Carson William H. · CIK 0001824280 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,405

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted December 8, 2025.

SEC source: 0001824280-26-000002 · form4-03122026_040329.xml · nonDerivative · entry 1

Carson William H. · CIK 0001824280 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,405

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted December 8, 2025.

SEC source: 0001818522-26-000003 · form4-03042026_040340.xml · nonDerivative · entry 1

Overdorf Michael · CIK 0001818522 · EVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182,625

F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · price: This transaction was executed in multiple trades in prices ranging from $5.36 to $5.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001818525-26-000003 · form4-03042026_040338.xml · nonDerivative · entry 1

Yednock Ted · CIK 0001818525 · EVP & CHIEF INNOVATION OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,161

F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · price: This transaction was executed in multiple trades in prices ranging from $5.35 to $5.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001465994-26-000003 · form4-03042026_040334.xml · nonDerivative · entry 1

Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,700

F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · price: This transaction was executed in multiple trades in prices ranging from $5.34 to $5.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001734424-26-000003 · form4-03042026_040342.xml · nonDerivative · entry 1

Dananberg Jamie · CIK 0001734424 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,582

F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · price: This transaction was executed in multiple trades in prices ranging from $5.36 to $5.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001958523-26-000003 · form4-03042026_040336.xml · nonDerivative · entry 1

ARTIS DEAN RICHARD · CIK 0001958523 · EVP & CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,093

F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · price: This transaction was executed in multiple trades in prices ranging from $5.35 to $5.56, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001818522-26-000002 · form4-02242026_120238.xml · derivative · entry 2

Overdorf Michael · CIK 0001818522 · EVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2036-02-19

F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 19, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001818522-26-000002 · form4-02242026_120238.xml · nonDerivative · entry 1

Overdorf Michael · CIK 0001818522 · EVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,964

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 19 of each year, with the first 1/3rd vesting on February 19, 2027, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001818520-26-000001 · form4-02242026_120218.xml · derivative · entry 1

Love Douglas · CIK 0001818520 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,250,000

Underlying: Common Stock · 1,250,000 shares

Expires 2036-02-19

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 19, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001818525-26-000002 · form4-02242026_120245.xml · derivative · entry 2

Yednock Ted · CIK 0001818525 · EVP & CHIEF INNOVATION OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2036-02-19

F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 19, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001818525-26-000002 · form4-02242026_120245.xml · nonDerivative · entry 1

Yednock Ted · CIK 0001818525 · EVP & CHIEF INNOVATION OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,727

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 19 of each year, with the first 1/3rd vesting on February 19, 2027, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001465994-26-000002 · form4-02242026_120245.xml · derivative · entry 2

Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2036-02-19

F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 19, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001465994-26-000002 · form4-02242026_120245.xml · nonDerivative · entry 1

Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,265

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 19 of each year, with the first 1/3rd vesting on February 19, 2027, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001734424-26-000002 · form4-02242026_120253.xml · derivative · entry 2

Dananberg Jamie · CIK 0001734424 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires 2036-02-19

F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 19, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001734424-26-000002 · form4-02242026_120253.xml · nonDerivative · entry 1

Dananberg Jamie · CIK 0001734424 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,402

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 19 of each year, with the first 1/3rd vesting on February 19, 2027, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001958523-26-000002 · form4-02242026_120223.xml · derivative · entry 2

ARTIS DEAN RICHARD · CIK 0001958523 · EVP & CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2036-02-19

F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 19, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001958523-26-000002 · form4-02242026_120223.xml · nonDerivative · entry 1

ARTIS DEAN RICHARD · CIK 0001958523 · EVP & CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,987

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 19 of each year, with the first 1/3rd vesting on February 19, 2027, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001818522-26-000001 · form4-02202026_040205.xml · nonDerivative · entry 1

Overdorf Michael · CIK 0001818522 · EVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,464

F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · price: This transaction was executed in multiple trades in prices ranging from $4.93 to $5.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001818525-26-000001 · form4-02202026_040207.xml · nonDerivative · entry 1

Yednock Ted · CIK 0001818525 · EVP & CHIEF INNOVATION OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,227

F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · price: This transaction was executed in multiple trades in prices ranging from $4.925 to $5.17, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001465994-26-000001 · form4-02202026_040201.xml · nonDerivative · entry 1

Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,765

F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · price: This transaction was executed in multiple trades in prices ranging from $4.925 to $5.17, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001734424-26-000001 · form4-02202026_040203.xml · nonDerivative · entry 1

Dananberg Jamie · CIK 0001734424 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,152

F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · price: This transaction was executed in multiple trades in prices ranging from $4.93 to $5.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001958523-26-000001 · form4-02202026_040209.xml · nonDerivative · entry 1

ARTIS DEAN RICHARD · CIK 0001958523 · EVP & CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,487

F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · price: This transaction was executed in multiple trades in prices ranging from $4.925 to $5.155, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001824280-26-000001 · form4-01022026_040103.xml · nonDerivative · entry 1

Carson William H. · CIK 0001824280 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,405

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 17, 2025.

SEC source: 0001650126-25-000005 · form4-12032025_041212.xml · nonDerivative · entry 1

Choi Jung · CIK 0001650126 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 33,000

F1 · price: This transaction was executed in multiple trades in prices ranging from $4.165 to $4.215, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

F2 · ownership.nature: These shares are held by The Park Family Revocable Trust. The Reporting Person and her spouse are co-trustees of the trust.

SEC source: 0001824280-25-000007 · form4-12032025_041210.xml · nonDerivative · entry 1

Carson William H. · CIK 0001824280 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,290

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 17, 2025.

F2 · price: This transaction was executed in multiple trades in prices ranging from $4.43 to $4.50, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

SEC source: 0001315797-25-000007 · form4-11222025_021158.xml · nonDerivative · entry 2

Satter Muneer A · CIK 0001315797 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 9,728,637

F1 · shares: All shares were purchased by Alerce Medical Technology Partners, L.P. ("Alerce Medical"). The Reporting Person has sole voting and dispositive power over the shares held by Alerce Medical. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

F4 · price: This transaction was executed in multiple trades in prices ranging from $4.165 to $4.415, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

F3 · ownership.nature: As of November 21, 2025, includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager, as applicable, and, in each such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 7,773,659 shares that are held by Alerce Medical for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest therein.

SEC source: 0001315797-25-000007 · form4-11222025_021158.xml · nonDerivative · entry 1

Satter Muneer A · CIK 0001315797 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 9,306,024

F1 · shares: All shares were purchased by Alerce Medical Technology Partners, L.P. ("Alerce Medical"). The Reporting Person has sole voting and dispositive power over the shares held by Alerce Medical. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

F2 · price: This transaction was executed in multiple trades in prices ranging from $4.25 to $5.065, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

F3 · ownership.nature: As of November 21, 2025, includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager, as applicable, and, in each such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 7,773,659 shares that are held by Alerce Medical for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest therein.

SEC source: 0001315797-25-000006 · form4-11192025_091101.xml · nonDerivative · entry 3

Satter Muneer A · CIK 0001315797 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 8,906,024

F1 · shares: All shares were purchased by Alerce Medical Technology Partners, L.P. ("Alerce Medical"). The Reporting Person has sole voting and dispositive power over the shares held by Alerce Medical. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

F5 · price: This transaction was executed in multiple trades in prices ranging from $3.57 to $4.19, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

F3 · ownership.nature: As of November 19, 2025, includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager, as applicable, and, in each such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 6,951,046 shares that are held by Alerce Medical for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest therein.

SEC source: 0001315797-25-000006 · form4-11192025_091101.xml · nonDerivative · entry 2

Satter Muneer A · CIK 0001315797 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 8,406,024

F1 · shares: All shares were purchased by Alerce Medical Technology Partners, L.P. ("Alerce Medical"). The Reporting Person has sole voting and dispositive power over the shares held by Alerce Medical. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

F4 · price: This transaction was executed in multiple trades in prices ranging from $3.01 to $3.285, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

F3 · ownership.nature: As of November 19, 2025, includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager, as applicable, and, in each such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 6,951,046 shares that are held by Alerce Medical for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest therein.

SEC source: 0001315797-25-000006 · form4-11192025_091101.xml · nonDerivative · entry 1

Satter Muneer A · CIK 0001315797 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 7,906,024

F1 · shares: All shares were purchased by Alerce Medical Technology Partners, L.P. ("Alerce Medical"). The Reporting Person has sole voting and dispositive power over the shares held by Alerce Medical. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

F2 · price: This transaction was executed in multiple trades in prices ranging from $2.695 to $3.115, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

F3 · ownership.nature: As of November 19, 2025, includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager, as applicable, and, in each such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 6,951,046 shares that are held by Alerce Medical for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest therein.

SEC source: 0001824280-25-000006 · form4-10312025_041004.xml · nonDerivative · entry 1

Carson William H. · CIK 0001824280 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,175

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 17, 2025.

F2 · price: This transaction was executed in multiple trades in prices ranging from $3.15 o $3.20, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

SEC source: 0001824280-25-000005 · form4-10022025_081058.xml · nonDerivative · entry 1

Carson William H. · CIK 0001824280 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,060

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 17, 2025.

F2 · price: This transaction was executed in multiple trades in prices ranging from $3.035 o $3.08, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

SEC source: 0001415889-25-023679 · form4-09042025_040906.xml · nonDerivative · entry 1

Carson William H. · CIK 0001824280 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,945

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 17, 2025.

F2 · price: This transaction was executed in multiple trades in prices ranging from $2.06 to $2.115, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

SEC source: 0001415889-25-020861 · form4-08012025_040819.xml · nonDerivative · entry 1

Carson William H. · CIK 0001824280 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,830

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 17, 2025.

F2 · price: This transaction was executed in multiple trades in prices ranging from $2.37 to $2.44, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

SEC source: 0001415889-25-019836 · form4-07162025_040701.xml · nonDerivative · entry 1

Overdorf Michael · CIK 0001818522 · EVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,689

F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · price: This transaction was executed in multiple trades in prices ranging from $2.57 to $2.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001415889-25-019838 · form4-07162025_040706.xml · nonDerivative · entry 1

Yednock Ted · CIK 0001818525 · EVP & CHIEF INNOVATION OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,084

F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · price: This transaction was executed in multiple trades in prices ranging from $2.57 to $2.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001415889-25-019837 · form4-07162025_040704.xml · nonDerivative · entry 1

Lew Jennifer · CIK 0001465994 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,616

F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · price: This transaction was executed in multiple trades in prices ranging from $2.58 to $2.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.